FMP

FMP

Enter

PDSB - PDS Biotechnology Co...

Financial Summary of PDS Biotechnology Corporation(PDSB), PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing mul

photo-url-https://financialmodelingprep.com/image-stock/PDSB.png

PDS Biotechnology Corporation

PDSB

NASDAQ

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

3.24 USD

0.04 (1.23%)

About

ceo

Dr. Frank K. Bedu-Addo Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.pdsbiotech.com

exchange

NASDAQ

Description

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related prot...

CIK

0001472091

ISIN

US70465T1079

CUSIP

70465T107

Address

25B Vreeland Road

Phone

800 208 3343

Country

US

Employee

25

IPO Date

Sep 30, 2015

Summary

CIK

0001472091

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

70465T107

ISIN

US70465T1079

Country

US

Price

3.24

Beta

1.72

Volume Avg.

930.29k

Market Cap

118.84M

Shares

-

52-Week

2.59-10.27

DCF

1.06

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.33

P/B

-

Website

https://www.pdsbiotech.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest PDSB News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep